CVR number 40685693
Industry 64.9900 Other financial service activities, except insurance and pension funding n.e.c.

JBN Biotech ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...
Bankruptcy Risk 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Bankruptcy risk for industry  0.4% 0.4% 0.4% 0.4% 0.4%  
Bankruptcy risk  0.0% 2.8% 2.4% 2.0% 1.8%  
Credit score (0-100)  0 59 62 68 70  
Credit rating  N/A BBB BBB A A  
Credit limit (kDKK)  0.0 0.0 0.3 5.2 14.6  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Gross profit  0.0 -16.0 -16.2 -25.0 -20.2  
EBITDA  0.0 -16.0 -16.2 -25.0 -20.2  
EBIT  0.0 -16.0 -16.2 -25.0 -20.2  
Pre-tax profit (PTP)  0.0 4,073.3 31,772.7 -278.9 -354.8  
Net earnings  0.0 4,337.3 31,880.6 -184.5 -263.3  
Pre-tax profit without non-rec. items  0.0 4,073 31,773 -279 -355  
 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Tangible assets total  0.0 0.0 0.0 0.0 0.0  
Shareholders equity total  0.0 3,731 35,612 35,427 35,164  
Interest-bearing liabilities  0.0 13,069 3,599 1,133 1,196  
Balance sheet total (assets)  0.0 30,247 49,211 46,859 46,968  
Net Debt  0.0 13,051 3,575 1,110 1,175  
 
See the entire balance sheet

Volume 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 -16.0 -16.2 -25.0 -20.2  
Gross profit growth  0.0% 0.0% -1.0% -54.6% 19.2%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 30,247 49,211 46,859 46,968  
Balance sheet change%  0.0% 0.0% 62.7% -4.8% 0.2%  
Added value  0.0 -16.0 -16.2 -25.0 -20.2  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 0 0 0  
Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 -1.0 -2.0 -3.0 -4.0  

Profitability 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 100.0% 100.0% 100.0% 100.0%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 17.4% 81.2% 0.3% 0.1%  
ROI %  0.0% 31.3% 115.1% 0.3% 0.1%  
ROE %  0.0% 116.2% 162.1% -0.5% -0.7%  

Solidity 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Equity ratio %  0.0% 12.3% 72.4% 75.6% 74.9%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% -81,569.0% -22,127.4% -4,443.0% -5,819.2%  
Gearing %  0.0% 350.3% 10.1% 3.2% 3.4%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 18.1% 5.7% 17.1% 34.0%  

Liquidity 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Quick Ratio  0.0 0.0 0.0 0.0 0.0  
Current Ratio  0.0 0.0 0.0 0.0 0.0  
Cash and cash equivalent  0.0 17.8 23.5 22.5 21.3  

Capital use efficiency 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 -26,085.6 -13,468.1 -11,303.0 -11,627.3  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
2021/6
2021
2022/6
2022
2023/6
2023
2024/6
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0